Research ExplorerPublicationsAn open-label, phase I/II trial to determine the maximum tol...

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Standard

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. / Fiedler, Walter; Montesinos, Pau; Schliemann, Christoph; Middeke, Jan; Vasu, Sumithira; Scholz, Christian W; Esteve, Jordi; Mondal, Shoubhik; Rüter, Björn; Burkard, Ute; Osswald, Annika; Blum, William.

In: HAEMATOLOGICA, Vol. 107, No. 12, 01.12.2022, p. 2977-2982.

Research output: SCORING: Contribution to journal › Letter › Research › peer-review

Harvard

Fiedler, W, Montesinos, P, Schliemann, C, Middeke, J, Vasu, S, Scholz, CW, Esteve, J, Mondal, S, Rüter, B, Burkard, U, Osswald, A & Blum, W 2022, 'An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia', HAEMATOLOGICA, vol. 107, no. 12, pp. 2977-2982. https://doi.org/10.3324/haematol.2022.281128

APA

Fiedler, W., Montesinos, P., Schliemann, C., Middeke, J., Vasu, S., Scholz, C. W., Esteve, J., Mondal, S., Rüter, B., Burkard, U., Osswald, A., & Blum, W. (2022). An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. HAEMATOLOGICA, 107(12), 2977-2982. https://doi.org/10.3324/haematol.2022.281128

Vancouver

Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW et al. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. HAEMATOLOGICA. 2022 Dec 1;107(12):2977-2982. https://doi.org/10.3324/haematol.2022.281128

Bibtex

@article{5b6634b2ce05453493fbc089f96cd16a,
title = "An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia",
abstract = "Not available.",
author = "Walter Fiedler and Pau Montesinos and Christoph Schliemann and Jan Middeke and Sumithira Vasu and Scholz, {Christian W} and Jordi Esteve and Shoubhik Mondal and Bj{\"o}rn R{\"u}ter and Ute Burkard and Annika Osswald and William Blum",
year = "2022",
month = dec,
day = "1",
doi = "10.3324/haematol.2022.281128",
language = "English",
volume = "107",
pages = "2977--2982",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

RIS

TY - JOUR

T1 - An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

AU - Fiedler, Walter

AU - Montesinos, Pau

AU - Schliemann, Christoph

AU - Middeke, Jan

AU - Vasu, Sumithira

AU - Scholz, Christian W

AU - Esteve, Jordi

AU - Mondal, Shoubhik

AU - Rüter, Björn

AU - Burkard, Ute

AU - Osswald, Annika

AU - Blum, William

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Not available.

AB - Not available.

U2 - 10.3324/haematol.2022.281128

DO - 10.3324/haematol.2022.281128

M3 - Letter

C2 - 36005556

VL - 107

SP - 2977

EP - 2982

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 12

ER -